Investigation Launched into EyePoint Pharmaceuticals after Share Price Plunge of 80%

EyePoint Pharmaceuticals Faces Potential Securities Claims

In a shocking turn of events, EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced that its Phase 3 LUCIA trial of DURAVYU has not met its primary endpoint of non-inferiority to the on-label treatment aflibercept for wet age-related macular degeneration. As a result, the company’s stock has plummeted by approximately 80%, causing significant concern among investors.

CEO Jay S. Duker initially reassured stakeholders during a call on August 6, 2025, stating that the LUGANO and LUCIA trials were aligned closely with the FDA's requirements. Moreover, he indicated that a positive outcome was anticipated. However, the reality turned out to be vastly different when the trial results were announced, raising serious questions about the misleading nature of prior statements regarding the study’s alignment with regulatory standards.

After the announcement on October 19, 2026, when it became clear that the LUCIA trial did not achieve the desired results, EYPT shares dropped dramatically. The trial results depicted that DURAVYU only improved visual acuity by roughly 2.5 letters, falling short against the 6.1 letters improvement noted in the control group. This discrepancy raised alarm bells regarding the efficacy of the treatment being tested and the potential ramifications on the regulatory pathway previously promised.

The legal community has reacted swiftly to this situation. SueWallSt, powered by Levi Korsinsky LLP, a nationally recognized securities litigation firm, has launched an investigation into the matter. They are specifically looking into whether EyePoint made materially false or misleading statements that inflated the perception of the company’s soundness and its products’ efficacy.

Investors who bought EYPT stocks during the period leading up to the announcement and experienced financial losses are encouraged to participate in a legal review. They can contact Joseph E. Levi, Esq. via email or phone for further information on how to proceed.

Legal Recourse for Affected Investors

Investors worried about their losses can start gathering their brokerage records to ascertain their eligibility for potential claims. The investigation focuses on those who purchased EYPT stock based on statements that may have been deceptive regarding the drug’s trial outcomes and FDA approval process. It's important to note that participation in this legal action does not necessitate court appearances for most investors, as these matters are often resolved outside of the courtroom.

Conclusion

The saga unfolding with EyePoint Pharmaceuticals serves as a stark reminder of the volatility in the biotechnology sector and the importance of transparency in clinical trials. As investors reel from the unexpected downturn, the unfolding investigation could pave the way for possible recovery options for affected shareholders. For those considering participation in this legal recourse, time is of the essence, and obtaining the necessary documentation is crucial for submission.

Should you find yourself affected or have any concerns regarding your investments, now is the time to seek guidance and explore your options in the wake of this alarming development.